ConductScience.org, home

Paper9869576

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Zhou XJ and 8 others. Antimicrob Agents Chemother, 1999. Cited by 80 papers, by iCite.

Cite this record

ConductScience Library. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Papers, record 9869576. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9869576

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1999
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
80
iCite
Relative citation ratio, by iCite
2.56
iCite
Revised in PubMed
2022-04-01
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou XJX J
2Sheiner LBL B
3D'Aquila RTR T
4Hughes MDM D
5Hirsch MSM S
6Fischl MAM A
7Johnson VAV A
8Myers MM
9Sommadossi JPJ P

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
DidanosineMajor topic
HIV InfectionsMajor topic
NevirapineMajor topic
ZidovudineMajor topic
Acquired Immunodeficiency Syndrome
Adolescent
Adult
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Models, Biological

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Wellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00000770A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and DidanosineBackground

Source ClinicalTrials.gov

Download CSV of trials

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18086138Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients.AIDS1994https://conductscience.org/library/papers/8086138PubMed
21416828Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1416828PubMed
37861025Clinical pharmacokinetics of nucleoside antiretroviral agents.J Infect Dis1995https://conductscience.org/library/papers/7861025PubMed
47533197High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.J Infect Dis1995https://conductscience.org/library/papers/7533197PubMed
57888117Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.AIDS1994https://conductscience.org/library/papers/7888117PubMed
67542804Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.Science1995https://conductscience.org/library/papers/7542804PubMed
78537676Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.J Infect Dis1996https://conductscience.org/library/papers/8537676PubMed
88568296Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.J Infect Dis1996https://conductscience.org/library/papers/8568296PubMed
98595509Studies of zidovudine in combination with didanosine and zalcitabine.J Acquir Immune Defic Syndr Hum Retrovirol1995https://conductscience.org/library/papers/8595509PubMed
108648207Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.J Infect Dis1996https://conductscience.org/library/papers/8648207PubMed
118633815
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Ann Intern Med1996https://conductscience.org/library/papers/8633815PubMed
128656777Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.Med Res Rev1996https://conductscience.org/library/papers/8656777PubMed
138924237Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine.AIDS1996https://conductscience.org/library/papers/8924237PubMed
148656502
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
JAMA1996https://conductscience.org/library/papers/8656502PubMed
158709686Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.Lancet1996https://conductscience.org/library/papers/8709686PubMed
168780817Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.AIDS1996https://conductscience.org/library/papers/8780817PubMed
178835201Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients.AIDS Res Hum Retroviruses1996https://conductscience.org/library/papers/8835201PubMed
188853730Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.AIDS1996https://conductscience.org/library/papers/8853730PubMed
198983858Clinical pharmacokinetics of zidovudine. An update.Clin Pharmacokinet1996https://conductscience.org/library/papers/8983858PubMed
208990341HIV-1 protease inhibitors. A review for clinicians.JAMA1997https://conductscience.org/library/papers/8990341PubMed

See all 36 referencesDownload CSV of references

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.

PMIDTitleJournalYearIn PapersSource
42549359The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19.ERJ Open Res2026https://conductscience.org/library/papers/42549359PubMed
41155646Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41155646PubMed
39542985Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.Clin Pharmacokinet2024https://conductscience.org/library/papers/39542985PubMed
33241266Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.J Antimicrob Chemother2021https://conductscience.org/library/papers/33241266PubMed
30670431Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/30670431PubMed
29899984Clinical and genetic determinants of nevirapine plasma trough concentration.SAGE Open Med2018https://conductscience.org/library/papers/29899984PubMed
27707991Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.J Antimicrob Chemother2017https://conductscience.org/library/papers/27707991PubMed
27528996Evaluation of antiretroviral therapy results in Blantyre, Malawi.Malawi Med J2005https://conductscience.org/library/papers/27528996PubMed
25064169Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.J Pharmacokinet Pharmacodyn2014https://conductscience.org/library/papers/25064169PubMed
24088395Caring for women living with HIV: gaps in the evidence.J Int AIDS Soc2013https://conductscience.org/library/papers/24088395PubMed
23877688Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23877688PubMed
23514375Clinical pharmacokinetics of antiretroviral drugs in older persons.Expert Opin Drug Metab Toxicol2013https://conductscience.org/library/papers/23514375PubMed
23459477Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23459477PubMed
22869579Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Antimicrob Agents Chemother2012https://conductscience.org/library/papers/22869579PubMed
22301417Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.AIDS2012https://conductscience.org/library/papers/22301417PubMed
22300396Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.Br J Clin Pharmacol2012https://conductscience.org/library/papers/22300396PubMed
21233689Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Ther Drug Monit2011https://conductscience.org/library/papers/21233689PubMed
20696882Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20696882PubMed
20038617Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20038617PubMed
19493344Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.BMC Infect Dis2009https://conductscience.org/library/papers/19493344PubMed

See all 36 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9869576

GET https://conductscience.org/api/papers/v1/9869576/references?page=2